Excalibur Management Corp reduced its position in Pfizer, Inc. (NYSE:PFE) by 0.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 180,019 shares of the biopharmaceutical company’s stock after selling 1,523 shares during the quarter. Pfizer comprises about 5.4% of Excalibur Management Corp’s investment portfolio, making the stock its 5th biggest position. Excalibur Management Corp’s holdings in Pfizer were worth $6,047,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fisher Asset Management LLC raised its position in shares of Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Pfizer by 1.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after buying an additional 377,404 shares during the period. Macquarie Group Ltd. raised its position in shares of Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after buying an additional 228,405 shares during the period. Boston Partners raised its position in shares of Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Pfizer by 1.2% in the 2nd quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock worth $622,562,000 after buying an additional 227,682 shares during the period. 69.09% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/13/pfizer-inc-pfe-shares-sold-by-excalibur-management-corp.html.

Pfizer, Inc. (NYSE PFE) traded down 0.523% during trading on Wednesday, reaching $35.185. The company had a trading volume of 9,587,277 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.75. The stock has a market cap of $209.26 billion, a P/E ratio of 25.739 and a beta of 1.00. The firm has a 50-day moving average price of $33.44 and a 200 day moving average price of $33.49.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s payout ratio is 94.12%.

Several research analysts recently weighed in on PFE shares. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 target price (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BidaskClub lowered Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $37.72.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 426,291 shares of company stock worth $14,475,911. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.